LATE BREAKING COHORT STUDY (JCS 2018) : Anticoagulation Therapy for Venous Thromboembolism in the Real World : From the COMMAND VTE Registry
-
- Yamashita Yugo
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Morimoto Takeshi
- Department of Clinical Epidemiology, Hyogo College of Medicine
-
- Amano Hidewo
- Department of Cardiovascular Medicine, Kurashiki Central Hospital
-
- Takase Toru
- Department of Cardiology, Kindai University Hospital
-
- Hiramori Seiichi
- Department of Cardiology, Kokura Memorial Hospital
-
- Kim Kitae
- Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital
-
- Konishi Takashi
- Department of Cardiology, Japanese Red Cross Otsu Hospital
-
- Akao Masaharu
- Department of Cardiology, National Hospital Organization Kyoto Medical Center
-
- Kobayashi Yohei
- Department of Cardiovascular Center, Osaka Red Cross Hospital
-
- Inoue Takeshi
- Department of Cardiology, Shiga Medical Center for Adults
-
- Oi Maki
- Department of Cardiology, Japanese Red Cross Wakayama Medical Center
-
- Izumi Toshiaki
- Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital
-
- Takahashi Kotaro
- Department of Cardiology, Shizuoka General Hospital
-
- Tada Tomohisa
- Department of Cardiology, Shizuoka General Hospital
-
- Chen Po-Min
- Department of Cardiology, Osaka Saiseikai Noe Hospital
-
- Murata Koichiro
- Department of Cardiology, Shizuoka City Shizuoka Hospital
-
- Tsuyuki Yoshiaki
- Division of Cardiology, Shimada Municipal Hospital
-
- Sakai Hiroshi
- Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science
-
- Saga Syunsuke
- Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center
-
- Sasa Tomoki
- Department of Cardiology, Kishiwada City Hospital
-
- Sakamoto Jiro
- Department of Cardiology, Tenri Hospital
-
- Yamada Chinatsu
- Department of Cardiovascular Medicine, Kyoto Okamoto Memorial Hospital
-
- Kinoshita Minako
- Department of Cardiology, Nishikobe Medical Center
-
- Togi Kiyonori
- Division of Cardiology, Nara Hospital, Kindai University Faculty of Medicine
-
- Ikeda Tomoyuki
- Department of Cardiology, Hikone Municipal Hospital
-
- Ishii Katsuhisa
- Department of Cardiology, Kansai Electric Power Hospital
-
- Kaneda Kazuhisa
- Department of Cardiology, Mitsubishi Kyoto Hospital
-
- Mabuchi Hiroshi
- Department of Cardiology, Koto Memorial Hospital
-
- Otani Hideo
- Department of Cardiovascular Medicine, Sugita Genpaku Memorial Obama Municipal Hospital
-
- Takabayashi Kensuke
- Department of Cardiology, Hirakata Kohsai Hospital
-
- Takahashi Mamoru
- Department of Cardiology, Shimabara Hospital
-
- Shiomi Hiroki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Makiyama Takeru
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Ono Koh
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Kimura Takeshi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
書誌事項
- タイトル別名
-
- Anticoagulation Therapy for Venous Thromboembolism in the Real World ― From the COMMAND VTE Registry ―
- Anticoagulation therapy for venous thromboembolism in the real world — from the Command VTE registry —
- Anticoagulation therapy for venous thromboembolism in the real world — from the COMMAND VTE Registry
この論文をさがす
説明
<p>Background:Venous thromboembolism (VTE) has a long-term risk of recurrence, which can be prevented by anticoagulation therapy.</p><p>Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic VTE between January 2010 and August 2014. The entire cohort was divided into the transient risk (n=855, 28%), unprovoked (n=1,477, 49%), and cancer groups (n=695, 23%). The rate of anticoagulation discontinuation was highest in the cancer group (transient risk: 37.3% vs. unprovoked: 21.4% vs. cancer: 43.5% at 1 year, P<0.001). The cumulative 5-year incidences of recurrent VTE, major bleeding and all-cause death were highest in the cancer group (recurrent VTE: 7.9% vs. 9.3% vs. 17.7%, P<0.001; major bleeding: 9.0% vs. 9.4% vs. 26.6%, P<0.001; and all-cause death: 17.4% vs. 15.3% vs. 73.1%, P<0.001). After discontinuation of anticoagulation therapy, the cumulative 3-year incidence of recurrent VTE was lowest in the transient risk group (transient risk: 6.1% vs. unprovoked: 15.3% vs. cancer: 13.2%, P=0.001). The cumulative 3-year incidence of recurrent VTE beyond 1 year was lower in patients on anticoagulation than in patients off anticoagulation at 1 year in the unprovoked group (on: 3.7% vs. off: 12.2%, P<0.001), but not in the transient risk and cancer groups (respectively, 1.6% vs. 2.5%, P=0.30; 5.6% vs. 8.6%, P=0.44).</p><p>Conclusions:The duration of anticoagulation therapy varied widely in discordance with current guideline recommendations. Optimal duration of anticoagulation therapy should be defined according to the risk of recurrent VTE and bleeding as well as death.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 82 (5), 1262-1270, 2018
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680084253696
-
- NII論文ID
- 130006725970
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 028956573
-
- PubMed
- 29576597
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可